Citi Pharma acquires 20% shareholding in Pakheim International Pharma

Material Disclosure

Citi Pharma Limited reports that it acquired a 20% shareholding in Pakheim International Pharma (Private) Limited under a Share Purchase Agreement dated May 6, 2026. This is the first tranche of a previously announced proposed acquisition of 100% of the target; the remaining shareholding is to be acquired subject to completion of applicable formalities and the agreement’s terms and conditions.

Key Findings

  • Citi Pharma has acquired 20% of Pakheim International Pharma (Private) Limited.
  • The transaction is the first tranche of a proposed acquisition of 100% of the target.
  • Acquisition of the remaining shareholding remains subject to applicable formalities and the Share Purchase Agreement’s terms and conditions.

Disclosure Details

Entities Involved
Citi Pharma Limited, Pakheim International Pharma (Private) Limited
Amount
20% shareholding acquired; proposed total acquisition of 100%
Impact
First tranche of the proposed acquisition of Pakheim International Pharma has been completed.
Risks
Acquisition of the remaining shareholding is subject to completion of applicable formalities and the terms and conditions of the Share Purchase Agreement.
⚡

Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.

More CPHL announcements

Built for PSX investors

Every filing.Summarised.

Key findings from every PSX announcement, right beside live prices and your portfolio.

Investify company announcements with result figures and filing highlights
Investify announcement summary with key findings from a PSX filing